Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
Just last week, Shkreli had identified Capricor as his next major biotech short target, co-authoring a lengthy report and ...
Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...
Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” ...
Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...
Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...
Capricor Therapeutics said Wednesday that its cell therapy significantly improved muscle and heart function in patients with ...
Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback